Modern Chinese Medicine Announces Year 2022 Interim Results; Expand distribution network to seize industry opportunities
- Written by Telegraph Magazine
PERFORMANCE HIGHLIGHTS
- The Group posted a consolidated revenue of approximately RMB196.1 million for the six months ended 30 June 2022, representing an increase of approximately 14.1%
- Gross profit increased by 9.9% to RMB86.4 million
- Net profit increased by 13.1% to approximately RMB49.9 million
- The increase in revenue was primarily driven by the surge in revenue generated from the sales of Vigour and Vitality Supplement Pill, Fever-removing and Detoxification Pill and Additional Ingredient Huoxiang Zheng Qi Pill
- Northeast, the PRC remained as the largest contributor (55.7%) to the Group’s total revenue
- The Group has currently established a distribution network for 83 distributors covering about 40 cities in the PRC
